Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II SABR + ILDR + PD-1 inhibitor + bevacizumab for driver gene-negative advanced NSCLC (second-line or later)
ChiCTR2600123755Phase 2Not yet recruiting
- Sponsor
- Shenshan Medical Centre, Memorial Hospital of Sun Yat-Sen University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Shenshan Medical Centre, Memorial Hospital of Sun Yat-Sen University. Primary endpoint: objective response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600123755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123755.